New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
07:34 EDTCPHDCepheid 2013 sales of CT/NG estimated $15M-$20M at William Blair
William Blair expects solid initial demand for Cepheid's just approved Xpert CT/NG from existing Xpert customers and projects 2013 sales between $15M-$20M on a worldwide basis. However, William Blair says it is not sure if Cepheid will be able to ship enough product to meet initial demand as it provided no update on the recent manufacturing issues. The firm keeps an Outperform rating on the stock.
News For CPHD From The Last 14 Days
Check below for free stories on CPHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 18, 2014
09:44 EDTCPHDCepheid trades sharply lower after earnings, levels to watch
Subscribe for More Information
09:24 EDTCPHDOn The Fly: Pre-market Movers
Subscribe for More Information
July 17, 2014
17:42 EDTCPHDCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
17:31 EDTCPHDCepheid sees significant step up in Q4 revenue
17:31 EDTCPHDCepheid sees Q3 non-GAAP EPS (1c)-1c, consensus (8c)
Subscribe for More Information
16:14 EDTCPHDCepheid sees FY14 adjusted EPS 10c-13c, may not compare to consensus (37c)
Subscribe for More Information
16:13 EDTCPHDCepheid reports Q2 EPS (14c), consensus (14c)
Reports Q2 revenue $116.5M, consensus $115.56M.
July 14, 2014
08:18 EDTCPHDCepheid Q2 results should beat expectations, says Wedbush
Wedbush thinks the high number of Cepheid's Infinity placements in 4Q13 and Q1 could boost the company's Q2 results. The firm keeps a $58 price target and Outperform rating on the shares.
July 10, 2014
10:05 EDTCPHDOn The Fly: Analyst Initiation Summary
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use